Cargando…

Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study

INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossov...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraj, Nesrine, Meddeb, Khaoula, Azouzi, Abdelbaki, Romdhani, Sana, Saad, Helmi Ben, Boussarsar, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934181/
https://www.ncbi.nlm.nih.gov/pubmed/33738034
http://dx.doi.org/10.11604/pamj.2020.37.346.24986
_version_ 1783660769906262016
author Fraj, Nesrine
Meddeb, Khaoula
Azouzi, Abdelbaki
Romdhani, Sana
Saad, Helmi Ben
Boussarsar, Mohamed
author_facet Fraj, Nesrine
Meddeb, Khaoula
Azouzi, Abdelbaki
Romdhani, Sana
Saad, Helmi Ben
Boussarsar, Mohamed
author_sort Fraj, Nesrine
collection PubMed
description INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossover, randomized, double-blind physiological trial. Patients admitted for hypoxemic acute respiratory failure with PaO2/FIO2 < 200mmHg despite optimized ventilation and sedation thus requiring non-depolarizing neuromuscular blocking agents (NMBAs), were enrolled. Patients received consecutively, in a random order, cisatracurium brand name (Nimbex®) and generic (Cisatrex®) over two-hour period separated by one-hour washout period. Neuromuscular function was monitored by a calibrated train-of-four (TOF) stimulation device. Paralysis time delay to reach TOF of 2/4, recovery kinetics and tolerance were monitored. The number needed to demonstrate a significant difference in time delays to reach a TOF of 2/4 between the two forms of cisatracurium was estimated at 22 patients. RESULTS: twenty-two patients were included. Eight (36.4%) had acute respiratory distress syndrome; 8(36.4%), acute exacerbation of chronic obstructive pulmonary disease and 3(13.6%), status asthmaticus. Median [IQR] SAPS II at admission, 28.5 [22, 41]. PaO2/FIO2, 121 [81, 156] mmHg. Paralysis time delays were respectively, 80 [50, 112] vs. 87 [65, 115] minutes, in Nimbex® group and Cisatrex® group; (p=0.579). Within the recovery period, the between two-studied drugs´ difference in TOF was at 0.25±0.96; p=0.64. There were no significant hemodynamic differences. CONCLUSION: the present study revealed no significant differences in efficacy nor in tolerance between cisatracurium brand name Nimbex® and generic name Cisatrex® in hypoxemic ventilated patients.
format Online
Article
Text
id pubmed-7934181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-79341812021-03-17 Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study Fraj, Nesrine Meddeb, Khaoula Azouzi, Abdelbaki Romdhani, Sana Saad, Helmi Ben Boussarsar, Mohamed Pan Afr Med J Research INTRODUCTION: use of generic drugs is common. However, there is still concern among patients and physicians that brand name drugs are more efficient. The aim of the study was to compare efficacy and tolerance between two forms of cisatracurium: brand name versus generic name. METHODS: it´s a crossover, randomized, double-blind physiological trial. Patients admitted for hypoxemic acute respiratory failure with PaO2/FIO2 < 200mmHg despite optimized ventilation and sedation thus requiring non-depolarizing neuromuscular blocking agents (NMBAs), were enrolled. Patients received consecutively, in a random order, cisatracurium brand name (Nimbex®) and generic (Cisatrex®) over two-hour period separated by one-hour washout period. Neuromuscular function was monitored by a calibrated train-of-four (TOF) stimulation device. Paralysis time delay to reach TOF of 2/4, recovery kinetics and tolerance were monitored. The number needed to demonstrate a significant difference in time delays to reach a TOF of 2/4 between the two forms of cisatracurium was estimated at 22 patients. RESULTS: twenty-two patients were included. Eight (36.4%) had acute respiratory distress syndrome; 8(36.4%), acute exacerbation of chronic obstructive pulmonary disease and 3(13.6%), status asthmaticus. Median [IQR] SAPS II at admission, 28.5 [22, 41]. PaO2/FIO2, 121 [81, 156] mmHg. Paralysis time delays were respectively, 80 [50, 112] vs. 87 [65, 115] minutes, in Nimbex® group and Cisatrex® group; (p=0.579). Within the recovery period, the between two-studied drugs´ difference in TOF was at 0.25±0.96; p=0.64. There were no significant hemodynamic differences. CONCLUSION: the present study revealed no significant differences in efficacy nor in tolerance between cisatracurium brand name Nimbex® and generic name Cisatrex® in hypoxemic ventilated patients. The African Field Epidemiology Network 2020-12-15 /pmc/articles/PMC7934181/ /pubmed/33738034 http://dx.doi.org/10.11604/pamj.2020.37.346.24986 Text en Copyright: Nesrine Fraj et al. https://creativecommons.org/licenses/by/4.0 The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Fraj, Nesrine
Meddeb, Khaoula
Azouzi, Abdelbaki
Romdhani, Sana
Saad, Helmi Ben
Boussarsar, Mohamed
Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title_full Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title_fullStr Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title_full_unstemmed Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title_short Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
title_sort compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (nimbex®) and generic (cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934181/
https://www.ncbi.nlm.nih.gov/pubmed/33738034
http://dx.doi.org/10.11604/pamj.2020.37.346.24986
work_keys_str_mv AT frajnesrine comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy
AT meddebkhaoula comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy
AT azouziabdelbaki comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy
AT romdhanisana comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy
AT saadhelmiben comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy
AT boussarsarmohamed comparedefficacyandtoleranceoftheneuromuscularblockadeinducedbybrandnamenimbexandgenericcisatrexofcisatracuriuminmechanicallyventilatedcriticallyillpatientsacrossoverdoubleblindrandomizedstudy